



Atty. Docket No.: 11111/2003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal, et al.
Serial No.: 10/666,898
Filed: September 19, 2003
Entitled: LECTIN COMPOSITIONS AND
METHODS FOR MODULATING
AN IMMUNE RESPONSE TO AN
ANTIGEN

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Conf. No.: Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Brenda M. Woods

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449; and
3. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 11111/2003. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: October 24, 2003

Mark J. Fitzgerald

Name: Mark J. Fitzgerald

Registration No.: 45,928

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.: 11111/2003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal, et al.
Serial No.: 10/666,898
Filed: September 19, 2003
Entitled: LECTIN COMPOSITIONS AND
METHODS FOR MODULATING
AN IMMUNE RESPONSE TO AN
ANTIGEN

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Conf. No.: Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A copy of the cited documents were submitted to the U.S. Patent and Trademark Office in the parent application, U.S. Serial No. 10/645,000. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

Date: October 24, 2003

Name: Mark J. FitzGerald

Registration No.: 45,928

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

USPTO Form 1449 Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 11111/2003		Serial No. 10/666,898		
				Applicant(s): Segal, et al.				
				Filing Date: September 19, 2003		Group: Not Yet Assigned		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	1.	Faulkner, L. et al., (2001), "IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells", <i>International Immunology</i> , 13(6):713-721						
	2.	Batova, A. et al., (1999), "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity <i>in Vitro</i> ", <i>Clinical Cancer Research</i> , 5:4259-4263.						
	3.	Frankel, A. et al., (1995), "IL2-Ricin Fusion Toxin Is Selectively Cytotoxic <i>in Vitro</i> to IL2 Receptor-Bearing Tumor Cells", <i>Bioconjugate Chem.</i> , 6:666-672.						
	4.	Gillies, S.D. et al., (1992), "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", <i>Proc. Natl. Acad. Sci. USA</i> , 89:1428-1432.						
	5.	Barker, E. et al., (1991), "Effect of a Chimeric Anti-Ganglioside G _{D2} Antibody on Cell-mediated Lysis of Human Neuroblastoma Cells", <i>Cancer Research</i> , 51:144-149.						
	6.	Gillies, S.D. et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody" <i>Hybridoma</i> , 10(3):347-356.						
	7.	Deliyannis, G. et al., (2000), "A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge", <i>PNAS</i> , 97(12):6676-6680.						
EXAMINER					DATE CONSIDERED			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>								
<small>**Copies of references not provided at the time of this submission.</small>								